News ledger · 52 dated stories · newest November 20, 2026 · updated November 20, 2026
GLP-1 Pricing and Regulatory News (November 2026): 52 Dated Stories
Provider price checks are our own reads of the providers' plan pages, terms and refund policies, dated to the day; FDA, court and trial items cite the primary document. Nothing here is a press release reprinted. The most recent price check is also reflected in the pricing database, the price index and llms.txt the same day.
Released: · Last reviewed:
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.
Categories: Approval, Enforcement, FDA, Label Expansion, Market & pricing, Pipeline, Policy, Safety, Safety Signal, Shortage, Verification, Warning Letter. Each story is dated to the event it reports; the October 2026 items were written on October 15, 2026.
Price Re-Read, November 20: Strut Health Raises Its Tirzepatide Price; Found and Yucca Health Lower Theirs; Mochi Health Prints Prices Again
We re-read 37 compounded tirzepatide and 38 compounded semaglutide programs on their own websites. NexLife’s standard prices are unchanged since November 6.
Up: Strut Health’s tirzepatide went from $149 to $219 a month; Zappy Health’s lowest tirzepatide price rose from $279 to $299 and its semaglutide from $159 to $209; HealthRX now charges $199 (tirzepatide) and $125 (semaglutide) after a $39 first month. Down: Found’s lowest cash tirzepatide price fell from $239 to $199 on a 12-month term; Yucca Health, which blocked our October read, now shows $139 month to month or $119 on a prepaid year; TelePep’s semaglutide fell from $169 to $119 on a 12-month charge. Newly priced: Mochi Health prints a $90 starting-dose tirzepatide and $60 semaglutide price plus a $79 or $49 monthly membership; Henry Meds’ legal price list shows semaglutide at $297 a month, but no injectable tirzepatide price. Black Friday: WellMedr ($69 and $39), Fridays (codes), Sunlight and yourEra show sale prices. Embody, BMI MD and He & She MD could not be re-read.
What it means for youRe-check the price on the program’s own page the day you pay; the single lowest figure for each drug in our index is a Black Friday sale price.
FDA Requires a NAION Warning on the Labels of All Approved GLP-1 Medicines
FDA’s November 9, 2026 Drug Safety Communication adds a warning about non-arteritic anterior ischemic optic neuropathy (NAION), a rare cause of sudden vision loss in one eye, to approved GLP-1 receptor agonist labels.
In FDA’s meta-analysis of trials, NAION occurred at 6.4 versus 3.8 events per 100,000 person-years, an absolute difference of about 2.6 per 100,000 person-years. FDA’s Sentinel analysis found no statistically significant difference against SGLT-2 inhibitors but an increased risk against DPP-4 inhibitors (hazard ratio 1.43). The change applies to approved products such as Zepbound, Mounjaro, Wegovy, Ozempic and Foundayo; compounded semaglutide and tirzepatide have no FDA label and the communication does not mention them.
What it means for youSudden vision loss or blurring in one eye needs urgent care; ask your program how to reach a clinician quickly if it happens.
Hims & Hers 10-Q: FTC Case Hearing Set for January 14, 2027; Compounded GLP-1s Now Offered “on a Limited Scale”
Hims & Hers’ third-quarter filing says it moved to dismiss the July 29, 2026 complaint by the FTC, Utah and Los Angeles County, with a hearing currently set for January 14, 2027, and that it accrued about $60 million for the matter.
The complaint alleges violations of the FTC Act and the Restore Online Shoppers’ Confidence Act after an investigation into subscription, cancellation, advertising and privacy practices; the allegations are unproven and the case is unresolved. The filing also says Hims shifted its U.S. weight-loss business toward branded GLP-1s in early 2026 and offers compounded GLP-1s only on a limited scale through 503A pharmacies. Hims’ own pages blocked our automated read, so its prices are not re-read.
What it means for youBefore subscribing to any program, read its cancellation terms and privacy policy; our privacy report compares 16 of them.
Lilly and Hims & Hers: Zepbound and Foundayo at Lilly’s Self-Pay Prices on the Hims Platform
A joint release says eligible Hims patients can buy Zepbound from $299 and Foundayo from $149 a month at Lilly’s self-pay prices; Hims says it has never offered compounded copies of Lilly’s GLP-1s and will not.
The release gives no Hims membership fee, start date or dispensing pharmacy, so the all-in monthly cost through Hims cannot yet be compared with compounded programs. On November 5, LifeMD said its affiliated pharmacy will also ship Lilly’s self-pay Zepbound and Foundayo (reported through a syndicated company release; LifeMD lists a $149 monthly program fee on its own site).
What it means for youBrand pricing through a telehealth platform is the manufacturer price plus the platform’s own fee; ask for both numbers.
Advertising Watchdog Tells Good Life Meds to Drop “Personalized” and Health-Benefit Claims for Compounded Tirzepatide+
In a challenge brought by Lilly, the National Advertising Division recommended that Good Life Meds stop claiming its compounded Tirzepatide+ products are personalized or deliver weight-loss, energy and other benefits.
NAD found the evidence offered concerned Lilly’s approved drugs and that nothing in the record addressed the safety of combining tirzepatide with the added ingredients. NAD is industry self-regulation, not a court or FDA; Good Life said it disagrees but will comply.
What it means for youTreat “personalized” and “plus” formula claims as marketing until a program explains what is in the vial and why.
Novo Nordisk Q3: Wegovy Pill Self-Pay $149 to $299; CagriSema U.S. Launch Planned for Early 2027, Subject to Approval
Novo’s third-quarter report gives the Wegovy pill’s self-pay price as $149 to $299 a month by dose and plans a U.S. CagriSema launch in early 2027 if FDA approves it.
No FDA decision on CagriSema had been announced when we checked. NovoCare’s introductory Wegovy pen offer for new patients ($199 for the first two fills) still runs to December 31, 2026.
What it means for youBrand self-pay terms change at year-end; re-check NovoCare in January before you budget for 2027.
Medicare’s Negotiated Price for Ozempic, Rybelsus and Wegovy Takes Effect January 1, 2027
CMS lists a negotiated Medicare price of $274 for a 30-day supply of semaglutide products (Ozempic, Rybelsus, Wegovy) from January 1, 2027.
The negotiated price applies inside Medicare Part D; it is not a cash price and does not change what telehealth programs charge. Separately, the Medicare GLP-1 Bridge’s $50 copay for eligible enrollees runs through December 31, 2027, and covers Foundayo, Wegovy and the Zepbound KwikPen, not vials.
What it means for youIf you have Medicare, compare the Bridge and your Part D plan before paying cash; people with type 2 diabetes are outside the Bridge.
FDA Warning Letter to Telehealth Seller RonanRx: “FDA-Approved Compounded” and “American Made” Claims Called Misleading
FDA’s October 30, 2026 letter (posted November 3) says RonanRx’s website and social posts misrepresented compounded semaglutide and tirzepatide, including a category labeled “FDA-Approved Compounded Medications”.
FDA says its records list no U.S.-registered manufacturer of semaglutide or tirzepatide ingredient for compounding, so “American made” and “farm-to-table” claims mislead. It was the only new GLP-1 warning letter posted between October 13 and November 17. Earlier in 2026, FDA sent similar telehealth letters to dozens of programs, including several this site reviews.
What it means for youNo compounded GLP-1 is FDA-approved; a program that says otherwise has failed a basic honesty check.
Class II Recall: Victory Medical Center Pharmacy’s Compounded Semaglutide and Tirzepatide Combination Vials
FDA’s November 11 enforcement report lists a voluntary recall, classified Class II on October 30, of semaglutide and tirzepatide vials combined with L-carnitine, niacinamide or vitamin B6, for lack of processing controls.
The vials were distributed in Colorado, Florida and Texas; lots ranged from 10 to 343 vials and the recall was listed as ongoing. It follows October Class II recalls by Carolina Infusion, Apothecary Pharma and Houston Rx for lack of assurance of sterility. None of these pharmacies is named on the plan pages of the programs we track that publish a pharmacy list.
What it means for youFind the pharmacy name on your vial label and ask your program whether your lot is affected.
HHS Draft Policy Would Allow 503A Compounding With Six Peptides, Reportedly Including BPC-157
A draft enforcement-discretion policy published October 30, 2026 says HHS does not intend to act against 503A compounding with peptides listed in its appendix; law-firm summaries list six, including BPC-157.
The HHS PDF with the list refused our automated read, so the peptide names are reported, not confirmed by us. The policy is a draft, covers no GLP-1, and does not make these peptides FDA-approved.
What it means for youPeptide add-ons sold beside GLP-1s remain unapproved; ask what evidence supports any add-on before paying for it.
Lilly Q3: Zepbound U.S. Revenue Up 48% to $5.3 Billion; Lower Realized Prices “Primarily Driven by Zepbound”
Lilly’s third-quarter release reports strong Zepbound growth while U.S. realized prices fell, mostly because of Zepbound.
Realized price is a net figure after rebates and discounts, not a cash price. Lilly’s self-pay pages refused our automated read on November 20, so its dose ladder is carried from a November 9 read.
What it means for youLilly’s results do not change any cash price on their own; compare the current LillyDirect ladder before switching to brand.
KFF 2026 Employer Survey: 18% of Firms With 200 or More Workers Cover GLP-1s for Weight Loss
KFF’s 2026 Employer Health Benefits Survey finds weight-loss GLP-1 coverage remains uncommon, and 12% of large firms without coverage say they recently stopped covering.
Coverage varies by firm size; most workers still face cash prices for weight-loss use.
What it means for youAsk HR whether your plan covers a GLP-1 for weight loss and what prior authorization requires before you start cash pay.
FDA Revises Import Alert 66-80 for GLP-1 Ingredients; 21% of 48 Evaluated Ingredient Sites Noncompliant
The revised alert lets FDA detain foreign GLP-1 active ingredients unless the firm and product are on its green list, and adds orforglipron.
FDA says 21% of the 48 GLP-1 ingredient sites it evaluated were noncompliant. Compounded semaglutide and tirzepatide depend on imported ingredient, and programs rarely say whose ingredient they use.
What it means for youAsk your program which pharmacy compounds your drug and where its ingredient comes from.
ResearchOfficial (peer-reviewed and company data)#
Research Roundup: ATTAIN-OSA, Retatrutide Trials, REDEFINE 9 and ObesityWeek Data
JAMA published ATTAIN-OSA (orforglipron for sleep apnea) on November 9; NEJM published retatrutide trials on October 21 and November 8; REDEFINE 9 (lower-dose CagriSema) appeared November 14; Lilly presented ObesityWeek data November 14 to 17.
None of these drugs or uses is newly approved. Lilly plans to file Foundayo for sleep apnea by the end of 2026 and retatrutide in the first quarter of 2027. FDA says retatrutide and cagrilintide cannot be used in compounding, so any “research” or compounded retatrutide is unlawful and of unknown quality.
What it means for youNothing new to buy yet; be wary of anyone selling retatrutide now.
Status Checks, November 20: 503B Decision Still Pending; No Material Verified Change in State Telehealth Rules
FDA’s proposal to keep tirzepatide, semaglutide and liraglutide off the 503B bulks list remains proposed with no final decision; semaglutide and tirzepatide injections are not on FDA’s shortage list, while liraglutide still is.
We found no material verified change in state telehealth or compounding rules, or in new compounded telehealth entrants, during the window. Brand self-pay terms for 2027 have not been announced; NovoCare’s current terms run to December 31, 2026.
What it means for youNo action needed; we will re-check these items on the next update.
Price Re-Read, October 15: Eden Drops Its Separate Membership, Four Programs Cut Prices, Henry Meds and Mochi Health Stop Printing a Compounded Price
We re-read 38 compounded tirzepatide and 32 compounded semaglutide programs on their own websites. NexLife’s standard plans are unchanged at $169/$159/$149/$139 (tirzepatide) and $139/$132/$125/$119 (semaglutide).
Eden now charges $129 a month for compounded tirzepatide and $99 for semaglutide, every month, and says there is no membership fee; our September file still carried a June figure of $329 for tirzepatide. CoreAge Rx lists tirzepatide “starting at $129” (was $149) and semaglutide at $79 (was $99). yourEra advertises $123 and $73 “as low as”. Sprout Health now bills every four weeks: $199 tirzepatide and $149 semaglutide, or $149 and $99 a month on a 12-month plan paid up front. Ozari Health’s own plans page confirms Ozari One ($125 tirzepatide, $86 semaglutide a month, billed every three months, not available in California) and Ozari Select ($235/$199/$175/$140 and $175/$145/$120/$99).
Henry Meds shows only a GLP-1 price “starting at $179/month” and its tirzepatide page returns 404; Mochi Health prints no compounded price on its weight-loss page; Fella Health says it is “temporarily pausing new sign-ups”. New in our index: Mondae, Collective, WellMedr, yourEra, Bodybuilding Health+, He & She MD, Pallas Health, Enhance.MD, MyDrHank, NextMeds and Alloy. BMI MD, Yucca Health, Ro and Hims & Hers blocked automated reads and keep their earlier figures.
What it means for cash-pay patientsThree programs, Mondae ($126), Eden ($129) and Strut Health ($149), now have lower standing month-to-month tirzepatide prices than NexLife ($169). Sale and prepaid offers go lower still; read the conditions before you compare.
Medicare Open Enrollment Opens; Lilly Will Report Third-Quarter Results on October 29
Medicare Open Enrollment runs October 15 to December 7, 2026, with changes taking effect January 1. Lilly’s October 15 release says it will announce third-quarter 2026 results on October 29.
For GLP-1 users on Medicare, the Medicare GLP-1 Bridge ($50 a month for eligible Part D enrollees, July 1, 2026 to December 31, 2027) covers Foundayo, Wegovy and the Zepbound KwikPen only. People whose qualifying condition is type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1. Eligibility depends on BMI and listed conditions; check Medicare.gov. Lilly’s October 29 results may show the self-pay mix for Zepbound and Foundayo; Lilly’s commercial savings terms run to December 31, 2026.
What it means for cash-pay patientsIf you are on Medicare and use a GLP-1 for weight, check Bridge eligibility before choosing a 2027 plan; cash-pay compounded programs are not part of Medicare.
CNN Reports Telehealth GLP-1 Prescribing to People With Anorexia
CNN reports clinicians seeing more patients with anorexia using GLP-1s, many obtained through telehealth with little screening; Hims & Hers told CNN eating-disorder screening is mandatory in its prescribing process.
The report adds pressure on asynchronous cash-pay intake. Whatever program you use, a legitimate intake asks about eating disorders, pregnancy, thyroid cancer history and pancreatitis, and a clinician reviews it before a prescription is written.
What it means for cash-pay patientsA program that never asks about your medical history before shipping medicine is a red flag, as FDA’s own GLP-1 page also says.
Walmart to Cover Ozempic and Mounjaro for Employees With Type 2 Diabetes in 2027, CNBC Reports; Still No Weight-Loss Coverage
According to CNBC, Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after a new prior authorization; GLP-1s for weight loss remain uncovered.
The details come from news reports (CNBC), not from a Walmart plan document. For employees seeking a GLP-1 for weight loss, the cash-pay market remains the route.
What it means for cash-pay patientsLarge-employer weight-loss coverage is still rare; budget for cash pay.
Ozari Health Splits Into Two Plans: Ozari One at $86 Semaglutide and $125 Tirzepatide, Billed Quarterly
A paid press release (October 12) announced Ozari One and Ozari Select; we confirmed the prices on Ozari’s own plans page on October 15.
Ozari One: semaglutide $86 a month (billed $258 every three months) and tirzepatide $125 (billed $375), not available in California. Ozari Select, all 50 states: semaglutide $175/$145/$120/$99 and tirzepatide $235/$199/$175/$140 a month on monthly, quarterly, six-month and annual billing. The same price applies at every dose.
What it means for cash-pay patientsThe $125 and $86 figures need three months paid up front; month to month, Ozari Select is $235 and $175.
FDA Posts Warning Letters to Two Websites Selling Unapproved Injectable Semaglutide
Letters 737806 (onlinegenericmedicine.com, dated September 23) and 737810 (cheapmedicineshop.com, dated September 24) were posted October 6, 2026.
FDA says the sites sold unapproved, misbranded injectable semaglutide under names such as “Semanat” and “Semanext”. These are not telehealth programs; they sell medicine without a prescription relationship.
What it means for cash-pay patients“Generic semaglutide” sold without a prescription is not a cheaper version of a telehealth program; FDA treats it as illegal.
FDA Updates Its GLP-1 Safety Page: Telehealth Red Flags, a 28-Day Vial Rule, and No Compounding of Retatrutide or Cagrilintide
The page “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” is marked current as of October 1, 2026.
It lists telehealth red flags for consumers, recommends discarding multi-dose compounded GLP-1 vials 28 days after first use, warns against semaglutide salt forms, says retatrutide and cagrilintide cannot be used in compounding under federal law, and reports adverse-event counts as of May 31, 2026: 990 for compounded semaglutide and more than 730 for compounded tirzepatide. Which sections changed on October 1 could not be determined. Our article checks the red flags against the programs we review.
What it means for cash-pay patientsBefore you pay, check the red flags you can check: no claim of sameness with an approved drug, a real clinician review, a clinician available after delivery, and a named pharmacy.
Rhode Island Medicaid Ends Coverage of GLP-1s Prescribed Only for Weight Loss
From October 1, 2026, Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, per a Tufts Health RITogether provider notice.
Coverage continues for type 2 diabetes and other FDA-approved indications such as cardiovascular risk reduction. Affected members must move to self-pay or stop treatment.
What it means for cash-pay patientsIf you lost Medicaid coverage, compare brand self-pay (LillyDirect, NovoCare) with compounded cash prices, and read the terms.
CMS BALANCE Page: Medicare GLP-1 Bridge Runs Through December 31, 2027
The CMS BALANCE Model page (modified September 29, 2026) states the Medicare GLP-1 Bridge has been extended through December 31, 2027 and includes an FAQ about “the BALANCE Model not launching in Medicare in 2027”.
The Bridge sits outside the Part D benefit: a $50 copay for eligible enrollees, no deductible, and no Part D sponsor opt-in. It covers Foundayo, Wegovy and the Zepbound KwikPen only.
What it means for cash-pay patientsMedicare enrollees who qualify pay $50 a month for an eligible brand GLP-1 through 2027.
Two Men Charged Over Counterfeit Ozempic Sourced From China, FDA Says
Federal prosecutors in the Middle District of Florida charged two Indian nationals with conspiracy and smuggling over counterfeit Ozempic distributed between July 2023 and April 2024. An indictment is an allegation only.
Buy brand GLP-1s only through licensed pharmacies, LillyDirect or NovoCare.
What it means for cash-pay patientsCounterfeits travel outside licensed pharmacies; a prescription filled by a named, licensed pharmacy is the safeguard.
FDA Warning Letter 738238 to Empower Pharmacy Over Compounded Tirzepatide and Semaglutide
Dated September 18 and posted September 22, 2026, the letter says Empower’s tirzepatide/niacinamide and semaglutide/cyanocobalamin products “appear to be essentially copies of FDA-approved semaglutide and tirzepatide products” and cites insanitary conditions.
FDA also says the volume of products suggests the claimed differences are “pretextual”. Programs that rely on additive formulations from Empower may switch pharmacies or formulations. Ask your program which pharmacy fills your prescription.
What it means for cash-pay patientsAsk which pharmacy fills your prescription and look it up; additive formulations are under scrutiny.
Novo Nordisk: About 90% of Wegovy Pill Prescriptions Are Self-Pay
Novo’s September 21 Capital Markets Day deck says the Wegovy pill has more than 7 million prescriptions year to date, about 90% self-pay, with partnerships across “9+ telehealth entities”.
NovoCare lists the Wegovy pill at $149 (1.5 mg), $199 (4 mg) and $299 (9 and 25 mg) a month for self-pay patients.
What it means for cash-pay patientsBrand semaglutide by mail is now a mainstream cash option; compare it with compounded prices before you choose.
Price Check, September 12: Embody, SnagRx and Yucca Health Verified on Their Own Pages and Ranked; the $119 Is a Non-Refundable Prepayment at One and a Checkout-Dated Promotion at the Other; NexLife’s Plan Page Now Says “Charged Monthly” and “No Contracts”
Five reads between September 4 and 12 closed the gap this site had carried since August 25: the three providers other comparison pages rank from citations are now recorded from their own plan pages, terms and refund policies, and they take the first, second and fifteenth places on the tirzepatide ranking. SnagRx and Embody share a $1,428 twelve-month total and a corporate parent (Modern Metabolic Medicine, Inc.); NexLife’s microdose rows move from verified to reported because the plan tiles still print the prior card.
Embody (joinem.co): tirzepatide $129 for one month as a sale price against a $349 regular price, $378 for three months, $738 for six, $1,428 for twelve ($119 a month); semaglutide $79 (regular $299), $228, $438, $828 ($69). The refund policy dated August 25, 2026 makes every payment final except on clinical ineligibility, and the “Save $200 instantly” banner carried three names on one day (Fall Sale, Labor Day Promo, Summer Start Promo) with no end date. Four dispensing pharmacies are named — Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine, Triad Rx — and the prescribers are OpenLoop Health. SnagRx (snagrx.com): $119 tirzepatide against a $399 list price and $69 semaglutide against $299, labelled Labor Day pricing through September 5 and “Fall Sale Discount Applied!” since September 9; the terms (July 27, 2026) limit promotional pricing to the period stated at checkout, after which standard pricing applies; the homepage countdown has read 00:00:00:00 since September 11 with the price unchanged. Month-to-month customers can cancel anytime; all sales are final; Louisiana is excluded. Same pharmacies, same prescriber network, same operator as Embody: Modern Metabolic Medicine, Inc., 1811 Silverside Road, Wilmington, Delaware.
Yucca Health (tryyucca.com): $258 monthly, $744 per three months ($248), $1,350 per six months ($225) with an auto-applied “Exclusive Lifetime Offer” on the six-month rate; flat at every dose; consultation, injection kit and two-day shipping included; no twelve-month plan; all sales final once the prescription is submitted (refund policy August 13, 2026, Brand Merchants Network LLC). $235 monthly, $597 quarterly ($199), $1,050 per six months ($175), $1,500 yearly ($125); semaglutide $175 / $145 / $120 / $99 — and states that payment is taken at checkout before provider review and refunded in full if treatment is not appropriate, and that stopping renewal does not end the current commitment. bmiMD: month-to-month rows verified (tirzepatide “as low as $179” against a $349.20 list price; semaglutide $119 against $228.60), a $50 cancellation fee in the August 24 policy, and a New Year’s banner still on the homepage.
NexLife: the standard cards are unchanged on all five reads ($169 / $159 / $149 / $139 tirzepatide; $139 / $132 / $125 / $119 semaglutide). The tirzepatide plan page states that every plan is “charged monthly as part of subscription” (12-month tile “Save $360”), “Same price at every dose. The microdose tirzepatide page leads with “$159 all-inclusive” but its plan tiles still print the prior $189 / $159 / $150 / $147 card, so the microdose rows are now reported rather than verified; the sublingual (ODT) program pages returned 404 on September 4 and 5. Value scores were recomputed against the new field minimums ($1,428 tirzepatide; No FDA press announcement touched GLP-1s or compounding between September 5 and 12, and no 503B bulks-list determination has been published. Every row is in the pricing database and on the September price-index snapshot; the changes are logged on the price history page.
Editorial takeawayThe two lowest prices on the market are real and they are both conditional: one ends when a checkout timer says so, the other ends only if a clinician says no. We rank them at the price on the page and print the condition on the row.
STEP Young: 40.4% of Children Aged 6 to 11 on Semaglutide No Longer Met the Obesity Threshold at 68 Weeks, Against 0% on Placebo; Full Data at ObesityWeek in November
Novo Nordisk reported topline phase 3 results on September 7, 2026: 165 children aged 6 to under 12 with obesity (more than 85% with class II or III obesity) were randomised to once-weekly semaglutide 1.7 mg or 2.4 mg by baseline weight or placebo, all with a reduced-calorie diet and increased activity, for 68 weeks with follow-up to 104 weeks. The primary endpoint — a greater BMI reduction than placebo — was met; 40.4% of treated children finished below the obesity threshold versus 0% on placebo.
Novo says safety and tolerability were consistent with earlier paediatric and adult semaglutide and liraglutide trials, with no new signals and none for growth or pubertal development; detailed results will be presented at ObesityWeek 2026 (November 14–17, Washington, DC). No regulatory filing timeline was given. Wegovy is currently approved from age 12.
This is an FDA-approved product studied under a protocol; it has no bearing on compounded semaglutide or tirzepatide, which are not FDA-approved, are not studied in children, and are not appropriate for anyone under 18 through a cash-pay telehealth program.
Editorial takeawayA large effect size in a small paediatric trial, headed for a conference in November and, presumably, a label-extension filing. Not a cash-pay story and not a compounding story.
Hims & Hers Faces a Securities Class Action Built on the FTC Complaint; Class Period August 4, 2025 – July 29, 2026, Lead-Plaintiff Deadline November 2, 2026
Hagens Berman announced on September 2, 2026 that a securities class action has been filed against Hims & Hers Health on behalf of investors who bought shares between August 4, 2025 and July 29, 2026. The complaint tracks the FTC’s July 29 allegations — health data shared with advertising platforms, charges taken at intake before a clinician review, subscriptions enrolled without informed consent — and cites a $4.32 (14.7%) one-day share-price fall on July 29 that erased more than $970 million of market value.
The FTC action (with Utah and Los Angeles County, filed in the Northern District of California) is a consumer-protection case; this one is an investor case about what the company told shareholders. Neither has been decided. Hims & Hers has said it will defend the FTC suit; it left mass-market compounded GLP-1s in March 2026 and now sells branded Novo Nordisk products.
For patients the practical question is unchanged from July: read the billing and cancellation terms of any telehealth program before paying, and prefer programs that publish their refund policy with a date. Our cancellation and refund guide and the refund test apply the same test to the cheapest compounded tirzepatide programs.
Editorial takeawayLitigation on two fronts, no rulings yet. It is a reminder that “cancel anytime” and “charged at intake” are contract terms worth reading before the first payment.
NexLife Announces Flat-Rate September Cards for Four Protocols: Microdose Tirzepatide $129–$159, Sublingual Tirzepatide $199–$229 — the Microdose Page Still Printed the Old Card on September 9
A press release dated August 31, 2026 (distributed on GlobeNewswire September 1) restates NexLife’s standard cards — injectable tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 by term — and adds four ranges: microdose semaglutide $110–$129, microdose tirzepatide $129–$159, sublingual semaglutide $165–$199, sublingual tirzepatide $199–$229 per month, all “same price at every dose” with no membership fee.
The release quotes Medical Director Dr. Adam Kennah (“the dose a patient starts on is almost never the dose they stay on”) and describes independent lab results on every batch for potency, sterility, pH and endotoxins. We treat press-release figures as announced until the live program page matches. On September 4, 5 and 9 the standard tirzepatide and semaglutide plan pages matched; the microdose tirzepatide program page still printed the prior card ($189 / $159 / $150 / $147, “From $147/Mo” in its title) on every read; the sublingual program pages could not be located. NexLife’s FAQ (read September 9) lists “microdose semaglutide starting at $129” and “sublingual tirzepatide starting at $229”.
NexLife is a commercial partner of this site. The price index shows its microdose row as announced, not verified, and its verification log records each day’s read.
Editorial takeawayThe $129 microdose figure is real as an announcement and still unverified as a page price. Until the program page prints it, budget on the $147 the page shows — or on the standard $139 plan, which is verified.
FDA Approves Mounjaro (Tirzepatide) to Lower Cardiovascular Risk in Adults with Type 2 Diabetes
On August 28, 2026 the FDA added a cardiovascular indication to Mounjaro: lowering the risk of major adverse cardiovascular events (CV death, non-fatal heart attack, non-fatal stroke) in adults with type 2 diabetes at high risk, on the SURPASS-CVOT trial against Trulicity.
Eli Lilly announced the approval on August 28, 2026. The indication rests on SURPASS-CVOT, a head-to-head cardiovascular outcomes trial of tirzepatide against dulaglutide (Trulicity) 1.5 mg in 13,299 adults with type 2 diabetes and established cardiovascular disease across 640 sites in 30 countries, followed for a median of 210.1 weeks. The MACE-3 hazard ratio was 0.92 (95.3% CI 0.83–1.01), an 8% lower event rate than an active comparator that itself has a proven cardiovascular benefit.
The label change applies to the FDA-approved product, Mounjaro, dispensed by pharmacies under Lilly’s quality system. It says nothing about compounded tirzepatide, which is not FDA-approved, is not the same product, and carries none of Mounjaro’s labelled indications. A telehealth page that cites SURPASS-CVOT to sell a compounded vial is borrowing evidence that does not transfer.
For readers comparing costs: Mounjaro’s list price is about $1,000 a month without coverage; the Lilly savings card can bring a commercially insured type 2 diabetes patient to $25; Medicare’s GLP-1 Bridge covers Zepbound and Foundayo (not Mounjaro) at $50 for obesity. The cardiovascular indication may change how insurers treat prior authorisation for patients with diabetes and heart disease — check your plan’s criteria.
Editorial takeawayThe first tirzepatide cardiovascular indication belongs to the FDA-approved product only. Compounded tirzepatide does not inherit it, and any provider implying otherwise is making a claim the FDA has already warned telehealth companies about.
Lilly: Real-World Claims Study Links Zepbound to Up to 38% Lower Healthcare Costs at 12 Months in Adults Over 55 — With the Drug’s Own Cost Excluded
Published in Diabetes, Obesity and Metabolism and announced by Lilly on August 26, 2026: 15,843 adults aged 55+ with obesity or overweight who started Zepbound were matched 1:1 with untreated controls in Komodo claims data. Costs were up to 15% lower ($181 per patient per month) at six months and up to 38% lower ($607) at twelve. The analysis excluded the price of Zepbound itself.
The population had a mean age of 64.5 and a BMI of 30 or more (or 27 with an obesity-related complication); enrolment ran from November 2023 to September 2025 with at least twelve months of continuous prior coverage. Savings came from lower rates of hospital admissions and emergency visits. Lilly states that at twelve months the estimated savings exceeded the cost of Zepbound treatment, but the headline percentages themselves do not include the drug, because claims data do not capture Zepbound’s net price.
Why it matters for a cash-pay reader: the study is about the FDA-approved product at insured, net prices, not about compounded tirzepatide at $119–$169 a month. It is a strong argument for coverage and for the Medicare GLP-1 Bridge’s $50 copay; it says nothing about the safety or effectiveness of a compounded copy.
Editorial takeawayA manufacturer-funded claims analysis with a clear caveat in its own press release. Use it to argue for coverage, not to compare against a compounded program’s sticker price.
FTC, Utah and Los Angeles County Sue Hims & Hers Over Subscription Billing, Cancellation and Health-Data Sharing
The Federal Trade Commission, joined by Utah and the Los Angeles County Counsel, filed suit in the Northern District of California on July 29, 2026, alleging Hims & Hers charged consumers on intake before any consultation, obstructed cancellation, and shared sensitive health data with Meta, Snap and other advertising platforms.
The complaint says the company charged consumers for prescriptions immediately upon submitting intake forms while telling them a consultation would first decide whether treatment was appropriate; made cancellation difficult (phone, email or chat only at first, then an online button hidden behind multiple steps after 2023); and shared health information through customer lists and tracking technologies despite privacy promises. The FTC’s Bureau of Consumer Protection director described “consumers unknowingly locked into recurring subscriptions and the disclosure to third parties of consumers’ most private health information without their consent.”
Hims & Hers had already announced on March 9, 2026 that it would stop advertising compounded GLP-1s and shift to branded Novo Nordisk products. The FTC case is about subscription mechanics and data, not compounding — which is exactly why it matters to every reader of this site: the same patterns (charge-on-intake, hard cancellation, auto-renewal on multi-month plans, 72-hour notice windows) appear in the terms of the cheapest compounded tirzepatide programs we track.
This site’s reviews now quote each provider’s refund and cancellation policy with its last-updated date. Read the cancellation and refund guide before prepaying any plan.
Editorial takeawayA federal consumer-protection action against the largest GLP-1 telehealth brand puts subscription billing and cancellation practices on the record. Before you enrol anywhere, get the billing date, the cancellation window and the renewal price in writing.
Retatrutide: Lilly Reports 21%–23% Weight Loss in TRIUMPH-2 and TRIUMPH-3, Plans an FDA Filing in Early 2027
Lilly’s triple-agonist retatrutide produced 21% average weight loss at 80 weeks in adults with type 2 diabetes (TRIUMPH-2) and 23% in adults with cardiovascular disease (TRIUMPH-3) at the highest doses, after 30% at 104 weeks in TRIUMPH-1 (May 2026). Lilly said it will seek FDA approval in the first quarter of 2027.
Reported on July 23, 2026: the two new phase 3 read-outs enrolled patients with either type 2 diabetes or established cardiovascular disease, populations that lose less than the comorbidity-free TRIUMPH-1 cohort. Lilly told CNBC it needed more time to gather manufacturing and quality-control data before filing, which moves a possible approval into 2027 at the earliest.
Retatrutide is not tirzepatide (it adds glucagon-receptor agonism to GIP and GLP-1) and it is not available: it is not FDA-approved, it is not on any shortage list, and there is no lawful compounded version. Any website offering “retatrutide” for weight loss in 2026 is selling an unapproved research chemical.
For patients on compounded tirzepatide, the practical effect is on the timeline: the FDA-approved dual-agonist products (Zepbound, Mounjaro) remain the only tirzepatide products with labelled indications until at least 2027, and the next-generation molecule will launch as a brand at a brand price.
Editorial takeawayDo not buy anything sold as retatrutide. The approval decision is a 2027 event; the 2026 market is tirzepatide and semaglutide.
Medicare GLP-1 Bridge Begins: $50 a Month for Wegovy, Zepbound and Foundayo for Eligible Part D Enrollees, July 1, 2026 – December 31, 2027
Medicare’s temporary GLP-1 Bridge started dispensing on July 1, 2026: a flat $50 copay for Wegovy (pill and injection), Zepbound (KwikPen) and Foundayo for Part D enrollees with a BMI of 35 or more, or 27 or more with a qualifying condition. The copay does not count toward the Part D deductible or the $2,100 out-of-pocket cap.
The program runs through December 31, 2027 and is separate from state Medicaid decisions. Eligibility is stricter than the drugs’ labels: BMI 35+, or 27+ with a condition such as heart disease or prediabetes, and enrolment in Part D. Plans process a Bridge prior authorisation; the manufacturers’ commercial savings cards still exclude Medicare and Medicaid beneficiaries by federal rule.
The price context is direct. A Medicare beneficiary who qualifies pays $50 a month for an FDA-approved product with a labelled indication; the cheapest compounded tirzepatide on a provider’s own page is $119 a month (twelve-month prepayment) and the cheapest all-in bundle $139 (see the price index). For eligible Medicare patients the Bridge is the cheaper and the safer route.
Medicare Part D enrollees who do not meet the BMI thresholds are left where everyone else is: manufacturer self-pay ($299–$449 Zepbound vials on LillyDirect; $349 Wegovy pens on NovoCare, $199 for the first two months) or compounded programs that are not FDA-approved.
Editorial takeawayIf you are on Medicare Part D and meet the thresholds, the $50 Bridge beats every cash price on this site. Ask your plan for the Bridge prior-authorisation form before considering a compounded program.
FDA Extends the Comment Period on Its Proposal to Keep Semaglutide, Tirzepatide and Liraglutide Off the 503B Bulks List to July 30, 2026
A Federal Register notice on June 26, 2026 (docket FDA-2018-N-3240) extended the comment period on the April 30 proposed determination by 30 days, to July 30, 2026. As of September 5, 2026 no final determination has been published; the proposal, not a final rule, is the current state.
The agency said a 30-day extension “appropriately balances allowing adequate time for interested persons to submit comments with avoiding significant delay.” The substance is unchanged: FDA proposes that the three molecules do not meet the clinical-need standard for outsourcing-facility bulk compounding, and that affordability is not clinical need.
Until a final determination is published, 503B facilities remain outside the bulks list for these molecules by default (they are not on it and the shortages are over), so the practical position is the same as in April: no lawful pathway for industrial-scale 503B compounding of tirzepatide; patient-specific 503A compounding on a valid prescription continues under state pharmacy law and FDA’s stated scrutiny of “essentially a copy” products.
Editorial takeawayThe comment window is closed and the decision is pending. Nothing about the extension reopens 503B compounding of tirzepatide; treat any provider claiming a 503B source as a question to ask, not a reassurance.
FDA Warning Letter to ProRx: 503B Outsourcing Facility Cited for Compounding Tirzepatide After Shortage Resolution
The FDA cited ProRx for compounding tirzepatide using bulk API after tirzepatide came off the drug shortage list and without inclusion on the 503B Bulks List. The letter also documented sterility, labeling, and adverse-event reporting deficiencies.
On May 18, 2026, the FDA issued a warning letter to ProRx, a 503B outsourcing facility, citing its continued production of compounded tirzepatide after the tirzepatide shortage was resolved in late 2024. Under section 503B of the FD&C Act, an outsourcing facility may compound a drug product from bulk drug substances only if the drug is on the FDA's 503B Bulks List or on the active shortage list. Tirzepatide was never on the Bulks List, and the shortage was resolved before the cited compounding activity.
Beyond the bulk-substance citation, the letter documented unsanitary conditions in sterile drug production, labeling deficiencies on several lots, and inadequate adverse-event reporting procedures. The agency required ProRx to cease compounding of the cited drug products and to submit a corrective-action plan within 15 working days.
ProRx reportedly ceased production of the cited products in April 2026, before the formal letter was issued. The cadence of these warning letters has been steady through 2025 and 2026: more than 55 warning letters were issued to online sellers of compounded GLP-1s in September 2025 alone, and additional letters have continued at roughly monthly intervals.
FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List
The Federal Register notice (docket 2026-08552) would close the legal pathway that allowed 503B outsourcing facilities to compound GLP-1 medications at industrial scale, even if a future shortage is declared. The comment period, originally to June 29, 2026, was extended to July 30, 2026; no final determination had been published as of September 5, 2026.
On April 30, 2026, the FDA published a proposed determination that semaglutide, tirzepatide, and liraglutide do not meet the statutory criteria for inclusion on the 503B Bulks List. Under 21 U.S.C. § 353b, an active pharmaceutical ingredient may be compounded in bulk by a 503B outsourcing facility only if it is on the FDA's published Bulks List or on the agency's drug shortage list. With semaglutide removed from the shortage list in February 2025 and tirzepatide removed in December 2024, the only remaining legal pathway for industrial-scale 503B compounding of these molecules was bulks-list inclusion.
The FDA's analysis concludes that there is no current clinical need for outsourcing-facility compounding of these three molecules from bulk API, since FDA-approved products (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza) are commercially available and meet patient need. The proposal explicitly rejects affordability and insurance access as constituting clinical need within the meaning of the statute.
The proposal does not affect 503A patient-specific compounding by state-licensed pharmacies, which remains legal where each prescription is supported by individualized medical-necessity documentation and the dispensing pharmacy operates under USP <797> sterile-compounding standards. It does, however, foreclose the path that enabled the 30%-of-supply compounding boom of 2024.
Foundayo (Orforglipron) Approved — First New-Molecule Oral GLP-1 for Chronic Weight Management
Eli Lilly's once-daily oral GLP-1, branded Foundayo, was approved by the FDA on April 1, 2026 under the Commissioner's National Priority Voucher pilot and shipped from April 9, 2026 at $149 a month for the lowest dose on LillyDirect. It is the first oral GLP-1 receptor agonist FDA-approved for chronic weight management.
On April 1, 2026 the FDA approved orforglipron (brand: Foundayo), Eli Lilly's once-daily small-molecule oral GLP-1 receptor agonist, for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Foundayo is the first new-molecule oral GLP-1 FDA-approved for weight management; the previously approved oral GLP-1, Rybelsus (semaglutide), is approved only for type 2 diabetes.
Pivotal evidence comes from the ATTAIN-1 trial program, which compared orforglipron to placebo and to active injectable comparators. Foundayo is not a tirzepatide product and is not a dual GLP-1 / GIP receptor agonist; it is a single GLP-1 receptor agonist administered as a once-daily pill.
The approval changes the market structure of the GLP-1 telehealth segment. Ro signed a deal with Eli Lilly in April 2026 to prescribe Foundayo alongside its existing semaglutide and tirzepatide offerings. Multiple other telehealth providers have signaled plans to add Foundayo to their formularies. The approval does not change the status of compounded tirzepatide, which remains a separate, non-FDA-approved product category.
Lilly Reports a Reaction-Related Impurity in All 10 Compounded Tirzepatide-with-B12 Samples It Tested and Calls for a Nationwide Recall
Eli Lilly said on March 12, 2026 that it detected “significant levels” of a reaction-related impurity in every one of ten compounded tirzepatide products containing vitamin B12 obtained from compounding pharmacies, telehealth companies and med spas, notified the FDA, and asked for a nationwide recall of tirzepatide-B12 products.
The finding concerns a combination some compounders market as a differentiator: tirzepatide with added B12 (and sometimes glycine or other additives). Lilly’s position is that the additive reacts with the peptide to form an impurity not present in the FDA-approved product; the compounding industry disputes the generalisation. The FDA had not, as of September 5, 2026, published its own recall order tied to this specific finding, but its February 6, 2026 statement already said it would restrict the ingredients used in mass-marketed compounded GLP-1s.
Several providers in our dataset state that their compounded tirzepatide “may include an additional ingredient such as vitamin B12 or glycine”. An added ingredient does not establish improved efficacy, safety or absorption, and this report is a specific reason to ask which formulation you will receive and to prefer the plain tirzepatide formulation unless a clinician gives you a reason.
Editorial takeawayAsk the pharmacy what is in the vial. A tirzepatide-B12 or tirzepatide-glycine combination is a compounded formulation with its own, unstudied chemistry; the March 2026 finding is the first published potency-and-purity evidence against one of them.
Hims & Hers Stops Advertising Compounded GLP-1s and Moves Its U.S. Weight-Loss Business to Branded Novo Nordisk Products
On March 9, 2026 Hims & Hers announced a “strategic shift”: it would cease advertising compounded GLP-1 offerings, transition existing patients to FDA-approved alternatives where clinically appropriate, offer compounded medication only when a provider determines clinical necessity, and add Ozempic and Wegovy (pill and injection) from Novo Nordisk later that month.
The announcement followed the FDA’s February 6 statement naming the company, the March 3 wave of 30 warning letters, and Novo Nordisk’s February 9 patent suit over a compounded semaglutide tablet Hims had advertised and then withdrew. The largest direct-to-consumer GLP-1 brand exiting mass-market compounding is the clearest market signal of 2026 that the shortage-era compounding business has ended for national platforms.
It also reshaped the cheapest-price table: Hims and Ro now sell brand products at manufacturer self-pay prices, while the $119–$139 compounded floor is held by smaller telehealth brands (Embody, SnagRx, NexLife) whose pages we read daily. Two of those — Embody and SnagRx — are the same company, Modern Metabolic Medicine, Inc. (see the price index).
Pricing for the Novo products through Hims was not disclosed in the announcement; NovoCare’s own self-pay Wegovy price is $349 a month for the pen ($199 for the first two months for new patients through December 31, 2026) and $199–$299 for the pill.
Editorial takeawayWhen the biggest platform stops selling compounded GLP-1s, the remaining cheap programs deserve more scrutiny, not less. Read who compounds, who prescribes, and what the refund policy says before you prepay.
FDA Sends 30 Warning Letters to Telehealth Companies Over Misleading Compounded GLP-1 Marketing
On March 3, 2026 the FDA issued 30 warning letters to telehealth companies for claims that compounded semaglutide and tirzepatide products are equivalent to, contain the same active ingredient as, or produce the same results as FDA-approved drugs, with 15 business days to correct the violations.
The letters follow the September 16, 2025 wave (55+ letters) and the February 6, 2026 “intent to take action” statement. Commissioner Marty Makary: “It’s a new era of enforcement. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action. Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to circumvent FDA’s approval process by mass-marketing compounded drugs.”
The claims the FDA objects to are the ones that appear on many provider pages: “same active ingredient as Zepbound”, “generic Mounjaro”, trial results quoted for a compounded vial. On this site every provider page states that compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro or Zepbound, and the SURMOUNT results are attributed to the FDA-approved injectable only.
Editorial takeawayA provider that still says “same as Zepbound” in September 2026 is either unaware of two rounds of FDA letters or ignoring them. Either way it is a signal about the rest of its compliance.
The FDA added a MASH indication to the Wegovy (semaglutide) label in early 2026, supported by ESSENCE trial data. The expansion broadens the FDA-approved GLP-1 indication set beyond weight management and OSA.
In early 2026 the FDA approved an indication expansion for Wegovy (semaglutide) to include metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), supported by data from the ESSENCE trial program. The approval makes Wegovy the second GLP-1 product to gain a non-weight-management indication after Zepbound's December 2024 OSA approval.
The MASH indication is significant because it brings GLP-1 therapy into the liver-disease space at scale. MASH is a leading driver of liver-related morbidity and mortality in U.S. adults, and prior to this approval, treatment options were limited to lifestyle intervention and one recently approved non-GLP-1 product.
The approval does not apply to compounded semaglutide, which remains a separate, non-FDA-approved product category and is not indicated for MASH or any other clinical indication.
TrumpRx Launches With Cash Prices for Brand GLP-1s (Zepbound from $299; Wegovy and Ozempic from about $150); Novo Nordisk Sues Hims & Hers Three Days Later
The TrumpRx cash-pay platform went live on February 6, 2026, listing manufacturer direct prices for FDA-approved GLP-1s: Zepbound from $299 (average about $346), Wegovy and Ozempic from about $150 (average about $399), Wegovy pill from $149. On February 9 Novo Nordisk filed a patent suit against Hims & Hers over a compounded semaglutide tablet.
TrumpRx does not sell drugs; it lists the manufacturers’ cash programs (LillyDirect, NovoCare) and lets uninsured or self-pay patients compare them with cash pharmacies. The listed prices are dose-dependent and match the December 2025 LillyDirect cut (Zepbound vials $299 / $399 / $449) and Novo’s November 2025 self-pay reset ($349, with a $199 introductory offer). Lilly’s prices “align with its agreement with the Trump administration” under the most-favoured-nation pricing deal.
The same week, Hims & Hers advertised and then withdrew a compounded semaglutide tablet; Novo Nordisk’s February 9 complaint alleged continued mass compounding with “inauthentic API” and comparative safety and efficacy claims against Wegovy. The FDA’s February 6 statement had named Hims specifically.
For price comparison, the brand self-pay floor is now $299 for the lowest Zepbound vial dose and $349 for a Wegovy pen ($199 for the first two months for new patients), versus $119–$169 for compounded tirzepatide programs that are not FDA-approved. The gap is $130–$330 a month, not the $900-plus that list-price comparisons imply.
Editorial takeawayCompare compounded prices with the manufacturer self-pay channels, not with list prices nobody pays. Our price index keeps both, dated.
FDA Announces Intent to Take Action Against Non-FDA-Approved GLP-1 Drugs
The February 6 press release confirmed that the agency would restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products and would pursue misleading direct-to-consumer advertising.
On February 6, 2026, the FDA issued a press release titled “FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs.” The release laid out the agency's enforcement posture against (1) compounded GLP-1 products that are not the result of individualized prescribing, (2) products containing salt forms of tirzepatide or semaglutide that the agency has not recognized as active pharmaceutical ingredients, and (3) marketing claims that imply equivalence to FDA-approved Mounjaro®, Zepbound®, Ozempic®, or Wegovy®.
The release built on the September 2025 wave of 55+ warning letters to online sellers of compounded GLP-1s and signaled the more structural action that would follow in April with the 503B Bulks-List exclusion proposal. The February release described the harms the agency was addressing: dosing errors from multi-dose vials, adverse-event reports exceeding 455 for compounded semaglutide and 320 for compounded tirzepatide as of early 2025, and counterfeit products entering the market through online channels.
The release was the first public confirmation from the agency that the shortage-era enforcement-discretion window had closed and would not re-open absent a new statutory pathway.
Lilly Cuts LillyDirect Zepbound Vial Prices to $299 / $399 / $449 a Month, Following Novo Nordisk’s $349 Self-Pay Reset
On December 1, 2025 Eli Lilly lowered self-pay Zepbound single-dose vials on LillyDirect: 2.5 mg $299 (was $349), 5 mg $399 (was $499), and 7.5 mg through 15 mg $449 (was $499) under the Zepbound Self Pay Journey Program. Novo Nordisk had cut Wegovy and Ozempic cash prices to $349 in mid-November 2025 with a $199 introductory offer.
The $449 price for the four higher doses applies on the first fill and on refills made within 45 days of the previous delivery; miss the window and the previous price applies. The 2.5 mg and 5 mg vials carry no refill condition. Novo’s April 2026 price guide sets the Wegovy pen at $349 for every standard dose ($399 for the 7.2 mg HD pen) and the Wegovy pill at $199 (1.5 mg) to $299 (9 mg, 25 mg), with $199 for the first two months for new patients through December 31, 2026.
These are the numbers a compounded tirzepatide price has to beat. At the doses most patients end up on (7.5 mg and above), brand tirzepatide is $449 a month on LillyDirect; the compounded programs in our index run $119 (prepaid) to $169 (month-to-month) and are not FDA-approved. Brand list prices without any program remain about $1,000–$1,350.
This site’s cost pages previously quoted LillyDirect vials “from about $349”; they were corrected to the December 2025 ladder on September 5, 2026.
Editorial takeawayBrand self-pay tirzepatide starts at $299 and is $449 at maintenance doses. Any comparison that still uses $349, $499 or the list price is out of date.
FDAWarning LetterDecember 1, 2025 (posted March 17, 2026)#
FDA Cites 503B Outsourcing Facility for cGMP Violations on Compounded GLP-1 Production
A 503B outsourcing facility in Cary, North Carolina received a CDER warning letter dated December 1, 2025 (publicly posted March 17, 2026) documenting multiple 503B and cGMP violations on compounded tirzepatide and semaglutide injections, including labeling deficiencies missing active ingredient identity, strength, and administration instructions.
The warning letter, issued by the FDA's Center for Drug Evaluation and Research (CDER), documented inspection findings from a May 12–15, 2025 inspection (Form FDA 483 issued May 15, 2025) and cited multiple violations of section 503B of the FD&C Act and current Good Manufacturing Practice (cGMP) requirements. Specific cited deficiencies included sterile-production conditions inconsistent with cGMP, multiple drug products lacking essential labeling — active and inactive ingredients, strength, dose, administration instructions — and procedural deficiencies in adverse-event reporting.
An earlier July 2025 recall by a different facility (GenoGenix) covered compounded semaglutide, tirzepatide, retatrutide, and a range of GLP-1 / vitamin combination injectables, on the basis of sterility problems documented during inspection.
Together with the May 2026 ProRx warning letter, these facility-level enforcement actions show that the FDA's enforcement focus is not limited to marketing language but extends to the underlying manufacturing operations of 503B outsourcing facilities producing compounded GLP-1s.
FDA Issues 55+ Warning Letters to Online Sellers of Compounded GLP-1s
On September 16, 2025, the FDA issued more than 55 warning letters to online sellers of compounded semaglutide and tirzepatide, citing misleading direct-to-consumer advertising as the primary basis.
The September 16, 2025 wave of warning letters targeted online sellers of compounded GLP-1 medications for misleading direct-to-consumer advertising in a range of forms: claims of equivalence to brand-name Wegovy® or Zepbound®, claims of FDA approval (which compounded products do not have), claims of “tested,” “verified,” or “FDA-registered” that conflated pharmacy registration with drug approval, and aggressive social-media targeting of patient populations on platforms including Instagram and TikTok.
One representative warning letter, to GLP-1 Solution (715883, 09/09/2025), cited the marketing of retatrutide — an investigational product not approved by the FDA — alongside compounded semaglutide and tirzepatide. The letter described retatrutide as an unapproved new drug and a misbranded drug under sections 505(a), 502(f)(1), 301(a), and 301(d) of the FD&C Act.
The September 2025 wave was framed by commentators at the time as “compliance theater,” and many telehealth providers and compounding pharmacies continued advertising. The follow-up February 2026 “intent to take action” press release and the May 2026 ProRx warning letter together established that the September 2025 letters were not the end of agency action but the beginning.
FDA Documents 455+ Adverse-Event Reports on Compounded Semaglutide, 320+ on Compounded Tirzepatide
Many of the reports involve dosing errors from patients self-administering incorrect doses from multi-dose vials, including some requiring hospitalization.
As of early 2025, the FDA's adverse-event tracking for compounded GLP-1 products had recorded more than 455 reports linked to compounded semaglutide and more than 320 reports linked to compounded tirzepatide. A meaningful share of these reports involved dosing errors from patients drawing incorrect doses from multi-dose vials — in some cases, ten-fold overdoses requiring hospitalization for severe nausea, vomiting, dehydration, or pancreatitis.
The dosing-error pattern is structural rather than incidental. Compounded GLP-1 products are commonly distributed in multi-dose vials with patient-administered syringes, whereas FDA-approved Wegovy, Zepbound, Ozempic, and Mounjaro are distributed in single-dose, fixed-dose pen injectors specifically designed to prevent over-aspiration. The FDA has cited the multi-dose vial format as a recurring contributor to the AE reports.
Counterfeit products entering the U.S. market through online channels have further reinforced the agency's enforcement focus. The agency has expanded import alerts on bulk API not on its recognized “green list” of FDA-inspected manufacturers.
Zepbound Approved for Obstructive Sleep Apnea in Adults with Obesity — First-Ever OSA Drug Indication
The FDA approved Zepbound (tirzepatide) in December 2024 for adults with moderate-to-severe obstructive sleep apnea and obesity, becoming the first prescription medication approved for OSA in the United States.
In December 2024 the FDA approved Zepbound (tirzepatide) for adults with moderate-to-severe obstructive sleep apnea and obesity, on the strength of the SURMOUNT-OSA trial program. SURMOUNT-OSA randomized adults with moderate-to-severe OSA and obesity to tirzepatide or placebo for 52 weeks. The trial demonstrated significant reductions in the apnea-hypopnea index (AHI) and in body weight, with a meaningful proportion of patients achieving control of OSA severity criteria.
Zepbound (tirzepatide) is manufactured by Eli Lilly and Company. It was originally approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. The December 2024 OSA indication is an expansion of that label.
The OSA indication is clinically significant because it is the first time a drug has been FDA-approved specifically for OSA in adults with obesity — a population for whom CPAP is the standard of care but adherence is often limited.
FDA Confirms Tirzepatide Shortage Resolved — Closing the 503A and 503B Compounding Windows
The FDA's October 2, 2024 statement that the tirzepatide shortage was resolved set in motion the regulatory cascade that culminated in the April 2026 503B Bulks-List exclusion proposal.
On October 2, 2024, the FDA published a statement determining that the shortage of tirzepatide injection had been resolved. The agency stated that, after consulting with the manufacturer, present and projected national demand could be met by FDA-approved product supply. Subsequent guidance set enforcement-discretion windows: state-licensed pharmacies (503A) and outsourcing facilities (503B) had defined wind-down periods after which compounding of tirzepatide from bulk substance was no longer permitted on shortage-based grounds.
The semaglutide shortage was separately resolved in February 2025, with similar 503A and 503B wind-down periods.
Between shortage resolution and the April 2026 503B Bulks-List exclusion proposal, the FDA's posture had been one of cumulative escalation: warning letters in September 2025 (55+), the February 2026 “intent to take action” press release, and the May 2026 ProRx warning letter all sit on this timeline.